Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating Canadians' Values for Drug Coverage Decision Making.

Shirin Rizzardo1, Nick Bansback2, Nick Dragojlovic3

  • 1Pharmaceutical Services Division, British Columbia Ministry of Health, Victoria, BC, Canada.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|March 6, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Using case-mixes to understand health resource utilization trajectories among older adults at high risk of falls who received baseline geriatrician-based Falls Prevention Clinic care.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

Experiences and Perceptions Within a Co-Created Drone Transport Initiative With Rural First Nation and Non-First Nation Communities: Semistructured Interview Study.

Journal of participatory medicine·2026
Same author

Myelin damage in radiologically isolated syndrome is associated with decreased processing speed.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

CDK1 and CEP97 cooperatively control centriole length to orchestrate ciliogenesis and developmental patterning.

Genes & development·2026
Same author

Productivity Loss and Health-Related Quality of Life Among People Living With Alopecia Areata: A Canada-Wide Cross-Sectional Study.

Journal of cutaneous medicine and surgery·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles
This summary is machine-generated.

Canadians prioritize drug reimbursement based on efficacy, safety, and disease severity. Factors like rarity were less valued, suggesting a need to align payer decisions with public priorities for fair drug funding.

Area of Science:

  • Health Economics
  • Health Policy
  • Pharmaceutical Outcomes

Background:

  • Rising drug costs challenge reimbursement decisions.
  • Payers increasingly use diverse values beyond cost and effectiveness.
  • Limited data exists on Canadian public priorities for drug reimbursement.

Purpose of the Study:

  • To quantify the societal importance of values in Canadian drug reimbursement.
  • To inform prioritization frameworks with public preferences.

Main Methods:

  • Online survey of 2539 Canadians (aged 19+).
  • Utilized analytic hierarchy process to rank and weight 13 prioritization values.
  • Assessed relative societal importance of various drug reimbursement criteria.
Keywords:
coveragedecision makingdrugs for rare diseaseshealth technology assessmentorphan drugspolicyreimbursementvalues

Related Experiment Videos

Main Results:

  • Top values included quality of life, disease severity, efficacy, and safety.
  • Drug characteristics like efficacy and safety were highly prioritized.
  • Rarity, socioeconomic status, and lifestyle choices received lower rankings.

Conclusions:

  • Canadian public prioritizes treatment and disease factors over rarity or unmet need.
  • Current reimbursement decision-making may not fully reflect public values.
  • Integrating public input into a Canadian drug reimbursement framework is recommended.